Policy· August 19, 2026 · 18 min read
CMS Bona Fide Marketing Rule: What the D.C. Circuit Teva Ruling Actually Revived
By Ran Chen#Policy#IRA Negotiation#Medicare Part D
Topic
Medicare Part D
Part D formulary design, IRA negotiated prices, out-of-pocket caps, LIS/Extra Help, and Medicare drug coverage policy.
Specialty· August 16, 2026 · 17 min read
Leqembi IQLIK Launches: Subcutaneous Lecanemab Moves to Specialty Pharmacy
Policy· August 16, 2026 · 15 min read
Ten PBMs Commit to TrumpRx Cash Prices in Real-Time Tools: The Policy Ledger
By Ran Chen#PBM#Payer Policy#Formulary Strategy
People· August 6, 2026 · 12 min read
Pharma Copay Foundations by the Numbers: 2024 IRS 990 Analysis
Pricing & Access· August 1, 2026 · 23 min read
Parkinson's Disease Treatment Access: From $0.08 Levodopa to Tavapadon
Pricing & Access· July 10, 2026 · 21 min read
AstraZeneca Portfolio Dossier: Farxiga Cliff, Enhertu Pivot, and Soliris Conversion
By Ran Chen#Orange Book#Purple Book#Medicare Part D
Pricing & Access· July 7, 2026 · 17 min read
BMS Portfolio Dossier: The Eliquis Cliff, Opdivo Lifecycle, and Cobenfy Bet
By Ran Chen#Orange Book#Purple Book#Medicare Part D
Pricing & Access· July 6, 2026 · 16 min read
Merck Portfolio Dossier: Keytruda QLEX, the Januvia Cliff, and a Post-2028 Pipeline
By Ran Chen#Purple Book#Orange Book#Biosimilars
Pricing & Access· July 5, 2026 · 16 min read
Rezdiffra (resmetirom) access: MASH drug coverage and UK MHRA authorization
Policy· June 30, 2026 · 17 min read
IRA Medicare Drug Negotiation Proposed Rule: Market-Access Analysis
By Ran Chen#IRA Negotiation#CMS#Market Access